Article

Dr Jennifer Martin Discusses How Insomnia Has Evolved & Affects In Insurance Coverage

Conference|SLEEP: American Academy of Sleep Medicine and Sleep Research Society (APSS) Annual Meeting

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, shares her thoughts on how non-pharmacologic treatments for the management of insomnia has evolved over the past few years and how the increased use of behavioral treatments might affect insurance coverage.

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, shares her thoughts on how non-pharmacologic treatments for the management of insomnia has evolved over the past few years and how the increased use of behavioral treatments might affect insurance coverage.

This video was taken on June 3, 2013, at the Sleep 2013 Conference in Baltimore, MD.

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Tom Belmon, CAP, GPBCH
Tom Belmont
Related Content
ASCO Guidelines | Image: ASCO
May 21st 2025

ASCO, Google Cloud Launch AI-Powered Tool to Help Doctors Access Guidelines

Mary Caffrey
The artificial intelligence-powered assistant will save clinicians time, especially in busy settings in community oncology.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Pill and water in hand | Image credit: New Africa – stock.adobe.com
May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein
Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
IPF letter blocks | Image credit: surasak – stock.adobe.com
May 19th 2025

Nerandomilast Slows Lung Function Decline in Patients With IPF

Hayden E. Klein
The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.
Doctor checking on sleeping patient in ICU | Image credit: Gorodenkoff – stock.adobe.com
May 19th 2025

Sleep Patterns, Predictors, and Pharmacologic Interventions in the ICU

Hayden E. Klein
Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo